General Updates

6 November 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Subject: Disclosure regarding grant of ESOPs and allotment of equity shares against exercise of vested ESOPs We hereby inform that the Nomination and Remuneration Committee of the Company at its meeting held today, i.e. on 6 November 2026 has approved the following: 1. (A) Grant of 69,028 stock options to the eligible employee(s) of the Company under the Cohance Lifesciences Limited – Employee Stock Option Plan 2026 (the “ESOP 2026”); and (B) Grant of 1,03,542 stock options to the eligible employee(s) of the Company under the Suven Pharmaceuticals Limited – Employee Stock Option Plan 2023 (the “ESOP 2023”); (The details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 on the above grants are annexed herewith as Annexure 1) 2. Allotment of 25,600 equity shares of the Company of face value of INR 1 each fully paid-up to the options grantees who have exercised the options vested to them under the ESOP 2023; (The details required to be disclosed under Regulation 10(c) read with Part E of Schedule I of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 is annexed herewith as Annexure 2) We request you to take the above on record. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K. Mishra Company Secretary & Compliance Officer Encl: as above Annexure 1 (A) Details of grant of employee stock options under the ESOP 2026 No Particulars Remarks 1 Brief details of Options 69,028 employee stock options (“Options”), which may be offered granted and granted in one or more tranches, each convertible into one equity share of the Company of face value of INR 1/-. 2 Whether the scheme is in Yes terms of SEBI (SBEB) Regulations, 2021 (if applicable) 3 Total number of shares The Options, upon exercise, shall result in allotment of 69,028 shares. covered by these options 4 Pricing formula The exercise price per option shall be decided by the Board or Nomination and Remuneration Committee and set out in the letter of grant. Provided that in any circumstances, the exercise price shall: (a) not be less than INR 325 (Rupees Three Hundred and Twenty Five only) for any grant that is made within 6 (six) months of the date of receipt of in-principle approval from the stock exchange following the approval of the ESOP 2026 by the shareholders of the Company, provided however that the grant to existing employees of the Company as on the effective date of the ESOP 2026 shall be made within 10 (ten) working days of the date of receipt of in-principle approval from the stock exchanges following the approval of the shareholders, at the exercise price of INR 325 (Rupees Three Hundred and Twenty Five only); or (b) in the case of any grant made after 6 (six) months of the date of receipt of in-principle approval from the stock exchanges following the approval of the shareholders, or any grant to existing employees made after 10 (ten) working days of receipt of in- principle approval from the stock exchanges as set out above, the exercise price shall not be at more than a 20% (twenty percent) discount to the average market price of the shares of the Company over a 21 (twenty-one) trading days’ period preceding one trading day prior to the grant date. 5 Options vested Options granted shall vest not earlier than minimum period of 1 (one) year and not later than maximum period of 8 (eight) years from the date of grant, subject to conditions as set out in the grant letter as issued to respective employees. The Nomination and Remuneration Committee may at its discretion, subject to applicable laws, change the vesting schedule provided that such change is not detrimental in the interest of the employees. 6 Time within which The exercise period shall be up to 3 years from the date of vesting of option may be exercised options. 7 Options exercised Not applicable 8 Money realized by Not applicable exercise of options 9 The total number of Not applicable shares arising as a result of exercise of option 10 Options lapsed Not applicable 11 Variation of terms of Not applicable options 12 Brief details of Significant terms of the Options have been given in the ESOP 2026, significant terms which can be accessed on the website of the Company at https://www.cohance.com/wp-content/uploads/2026/07/ESOP-2026- Plan-23Jul26-Final.pdf 13 Subsequent changes or Not applicable cancellation or exercise of such options 14 Diluted earnings per Not applicable share pursuant to issue of equity shares on exercise of options Annexure 3 (B) Details of grant of employee stock options under the ESOP 2023 No Particulars Remarks 1 Brief details of Options granted 1,03,542 employee stock options (“Options”), which may be offered and granted in one or more tranches, each convertible into one equity share of the Company of face value of INR 1/- 2 Whether the scheme is in terms Yes of SEBI (SBEB) Regulations, 2021 (if applicable) 3 Total number of shares covered The Options, upon exercise, shall result in allotment of 1,03,542 by these options shares. 4 Pricing formula All Options were granted at the exercise price of INR 495. 5 Options vested Options granted shall vest not earlier than minimum period of 1 (one) year and not later than maximum period of 10 (ten) years from the date of grant, subject to conditions as set out in the grant letter as issued to respective employees. The Nomination and Remuneration Committee may at its discretion, subject to applicable laws, change the vesting schedule provided that such change is not detrimental in the interest of the employees. 6 Time within which option may The exercise period shall be up to 3 years from the date of vesting be exercised of options. 7 Options exercised Not applicable 8 Money realized by exercise of Not applicable options 9 The total number of shares Not applicable arising as a result of exercise of option 10 Options lapsed Not applicable 11 Variation of terms of options Not applicable 12 Brief details of significant terms Significant terms of the Options have been given in the ESOP 2023, which can be accessed on the website of the Company at https://www.cohance.com/wp- content/uploads/2025/06/SuvenESOP2023Policy.pdf 13 Subsequent changes or Not applicable cancellation or exercise of such options 14 Diluted earnings per share Not applicable pursuant to issue of equity shares on exercise of options Annexure - 2 Details under Regulation 10(c) read with Part E of Schedule I of the SEBI (SBEB) Regulations No Particulars Remarks 1 Company name and Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals address of Registered Limited) Office 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai, Maharashtra, 400093 2 Name of the recognised BSE Limited (BSE) and Stock Exchanges on National Stock Exchange of India Limited (NSE) which the company's shares are listed 3 Filing date of the NSE: 19 February 2024 statement referred in regulation 10(b) of the BSE: 19 February 2024 SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognized Stock Exchange 4 Filing Number, if any NSE: Application No. 40156 BSE: Application No. 195357 5 Title of the Scheme Suven Pharmaceuticals Limited – Employee Stock Option Plan, pursuant to which shares 2023 are issued, if any 6 Kind of security to be Equity shares listed 7 Par value of the shares INR 1 per equity share 8 Date of issue of shares 6 November 2026 /Allotment date 9 Number of shares issued 25,600 and allotted 10 Share Certificate No., if N.A. applicable 11 Distinctive number of [Showing first 8,000 characters — download PDF for full document]